I-MAB/$NBP

14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX

About I-MAB

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.

Ticker

$NBP
Sector
Primary listing

Employees

32

I-MAB Metrics

BasicAdvanced
$460M
-
-$0.49
1.46
-

What the Analysts think about I-MAB

Analyst ratings (Buy, Hold, Sell) for I-MAB stock.

I-MAB Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

I-MAB Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NBP

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs